Journal
BLOOD
Volume 132, Issue 14, Pages 1507-1518Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2018-01-824607
Keywords
-
Categories
Funding
- National Institutes of Health National Cancer Institute Cancer Center Support [P30CA013330]
- New York State Department of Health (NYSTEM Program) [C029154]
- Leukemia & Lymphoma Society Translational Research grant [6471-15]
- AIDS Malignancy Consortium grant [UM1CA121947]
- Harry Eagle Scholarship from the Department of Cell Biology, Albert Einstein College of Medicine
- hematology/oncology fellowship program, Montefiore Medical Center
- Jacobi Medical Center
Ask authors/readers for more resources
Adult T-cell leukemia lymphoma (ATLL) is a rare T cell neoplasm that is endemic in Japanese, Caribbean, and Latin American populations. Most North American ATLL patients are of Caribbean descent and are characterized by high rates of chemo-refractory disease and worse prognosis compared with Japanese ATLL. To determine genomic differences between these 2 cohorts, we performed targeted exon sequencing on 30 North American ATLL patients and compared the results with the Japanese ATLL cases. Although the frequency of TP53 mutations was comparable, the mutation frequency in epigenetic and histone modifying genes (57%) was significantly higher, whereas the mutation frequency in JAK/STAT and T-cell receptor/NF-kappa B pathway genes was significantly lower. The most common type of epigenetic mutation is that affecting EP300 (20%). As a category, epigenetic mutations were associated with adverse prognosis. Dissimilarities with the Japanese cases were also revealed by RNA sequencing analysis of 9 primary patient samples. ATLL samples with a mutated EP300 gene have decreased total and acetyl p53 protein and a transcriptional signature reminiscent of p53-mutated cancers. Most importantly, decitabine has highly selective single-agent activity in the EP300-mutated ATLL samples, suggesting that decitabine treatment induces a synthetic lethal phenotype in EP300-mutated ATLL cells. In conclusion, we demonstrate that North American ATLL has a distinct genomic landscape that is characterized by frequent epigenetic mutations that are targetable preclinically with DNA methyltransferase inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available